

**Listing of Claims:**

Claims 1-33 (Cancelled).

34 (Previously presented) A pharmaceutical formulation comprising a homogeneous mixture of: (a) uncoated olanzapine or a pharmaceutically acceptable salt thereof as an active ingredient; (b) a monosaccharide and/or oligosaccharide and/or a reduced or oxidized form thereof; (c) a polysaccharide and optionally; d) one or more additional excipients.

35. (Previously presented) The pharmaceutical formulation of claim 34 wherein the formulation is prepared by a direct compression of the mixture into tablets in the absence of any solvent.

36. (Previously presented) The pharmaceutical formulation of claim 34 comprising 40 to 80 weight % of the component (b).

37. (Previously presented) The pharmaceutical formulation of claim 34 comprising 10 to 40 weight % of the polysaccharide.

38. (Previously presented) The pharmaceutical formulation of claim 34 additionally comprising (d) up to 15 weight % of a disintegrant.

39. (Previously presented) The pharmaceutical formulation claim 34 additionally comprising (e) 5 to 20 weight % of a binder.

40. (Previously presented) The pharmaceutical formulation of claim 34 additionally comprising (f) 0.25 to 5 weight % of a lubricant.
41. (Previously presented) The pharmaceutical formulation of claim 34 additionally comprising (g) 0.1 to 0.5 weight % of a glidant.
42. (Previously presented) The pharmaceutical formulation of claim 34, wherein the component (b) is selected from the group consisting of lactose, sucrose, dextrose, sorbitol, mannitol, lactitol, and mixtures thereof.
43. (Previously presented) The pharmaceutical formulation of claim 42, wherein the component (b) is lactose.
44. (Previously presented) The pharmaceutical formulation of claim 34, wherein the polysaccharide is selected from the group consisting of starch, cellulose, and mixtures thereof.
45. (Previously presented) The pharmaceutical formulation of claim 44, wherein the polysaccharide is cellulose.
46. (Previously presented) The pharmaceutical formulation of claim 34, wherein a mixture of 20 to 30 weight % of cellulose and 70 to 80 weight % of lactose is used as the components (b) and (c).
47. (Previously presented) The pharmaceutical formulation of claim 46 comprising 70 to 90

weight % of a mixture of 20 to 30 weight % of cellulose and 70 to 80 weight % of lactose;

8 to 12 weight % of a binder;

3 to 10 weight % of a disintegrant;

0.3 to 2 weight % of a lubricant; and

0.2 to 0.4 weight % of a glidant.

48 (Previously presented) The pharmaceutical formulation of claim 34 comprising olanzapine as the only pharmaceutically active ingredient.

49. (Previously presented) The pharmaceutical formulation of claim 34 having the form of an uncoated tablet.

50. (Previously presented) The pharmaceutical formulation of claim 34 wherein the active ingredient (a) is distributed in a matrix formed by ingredients (b), (c), and (d).

51. (Previously presented) The pharmaceutical formulation of claim 34 wherein formulation is in a tablet form which does not have a layered structure.